JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $100
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $103 to $100.
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $103 to $100.
